NCT01570049UnknownPhase 3
A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma
Shandong Lanjin Pharmaceuticals Co.,Ltd1 site in 1 country100 target enrollmentStarted: April 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Overall response rate (ORR=CR+PR) of bendamustine hydrochloride in patients who are refractory to rituximab therapy.
Study Overview
Brief Summary
The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.
Detailed Description
This is multicenter, open label study to evaluate the safety and efficacy of bendamustine HCl in patients with indolent Non-hodgkin's lymphoma and relapsed after rituximab treatment. This injection will be given through i.v. infusion in >= 60 minutes on days 1 and 2 of every 21-day treatment cycle. Patients will be treated for up to 8 cycles unless progressive disease or unacceptable toxicity take place. Patients will be followed for up to 1 year before evaluating progression free survival (PFS) and overall survival (OS).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 to 75 years
- •B-cell indolent lymphoma proved by biopsy, exclude CLL/SLL
- •Rituximab refractory or relapsed lymphoma patients
- •At least 1 measurable tumor with shortest diameter being of > 1.0cm and longest diameter being of > 1.5cm
- •ECOG PS ≤ 2
- •Anticipated Survival is more than 3 months
- •Hematopoietic function is normal during 14 days before enrollment (unless those abnormities related to lymphoma aggression), including: hemoglobin (Hb) ≥ 8.0g/dl (5.0mmol/L); absolute neutrophil count (ANC) ≥ 1.5X109/L; Platelet count (PLT) ≥ 80X109/L. Acceptable range for abnormities related to lymphoma aggression: Platelet count (PLT) ≥ 50X109/L; White blood cell count (WBC) ≥ 3.5X109/L; Absolute neutrophil count (ANC) ≥ 1.0X109/L
- •Female subjects should not be pregnant and breast-feed, should have contraceptive method during the clinical trial and 12 months thereafter.
- •Subject (or his/her legal representative) agrees to participate the trial and sign the informed consent form
Exclusion Criteria
- •Those who can not tolerate bendamustine treatment according to investigators view
- •Transferred to high grade malignant lymphoma (from low grade follicular lymphoma)
- •3b grade follicular lymphoma
- •With central nervous system diseases or medical history (e.g., central nervous system lymphoma or lymphoma related meningitis )
- •With other anticancer treatment during the last 4 weeks
- •Regularly administrated corticosteroid during the last 4 weeks, unless the dose is less or equivalent to 20mg/d prednisone
- •Had tumors or have other tumors, not including non-melanoma skin cancers and cervical carcinoma in situ be treated properly
- •Underwent surgical operation within 28 days before enrollment (exclude lymph node biopsy)
- •Renal disfunction: serum creatinine is more than 1.5 times of upper limit of normal value
- •Hepatic insufficiency: serum total bilirubin is > 1.5 times of upper limit of normal value; AST, ALT is > 2.5 times of upper limit of normal value
- •Known HIV infection or HBV, HCV related active infections; HBsAg is positive; HBcAb is positive and virus copy number is > 1000
- •For patients with other severe medical diseases interfering with their participations of this study(e.g., infections and diabetes not controlled well, gastric ulcer, other lung diseases, active autoimmune diseases), the suitability of participation is judged by investigators
- •Patients participated in other clinical studies and got medical treatments within 30 days prior to enrollment of this trial
- •Other medical and psychological conditions that influence the patients participation or signing of informed consent form
Arms & Interventions
Bendamustine
Experimental
Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
Intervention: Bendamustine (Drug)
Outcomes
Primary Outcomes
Overall response rate (ORR=CR+PR) of bendamustine hydrochloride in patients who are refractory to rituximab therapy.
Time Frame: 18 months
Secondary Outcomes
- Safety profile of Bendamustine hydrochloride in this patient population(18 months)
- Progression free survival (PFS)(18 months)
- Overall survival (OS)(18 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionIndolent B-Cell Non-Hodgkin's LymphomasNCT04569838Chia Tai Tianqing Pharmaceutical Group Co., Ltd.91
Completed
Phase 2
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaMantle Cell LymphomaNCT00891839Cephalon45
Unknown
Phase 3
Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic LeukemiaNeoplasmsLeukemiaChronic Lymphocytic LeukemiaNCT01657955Shandong Lanjin Pharmaceuticals Co.,Ltd96
Completed
Phase 2
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01109264Jiangsu Simcere Pharmaceutical Co., Ltd.147
Terminated
Phase 1
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple MyelomaMultiple MyelomaNCT01484626Loyola University3